Drugs / DWC202301
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06751121 Comparator | Feb 2024 → Apr 2025 | Helicobacter pylori infectious disease | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWC202301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06751121 ↗ |
| Route | Oral | “DWC202301 30 mg, capsule, orally” NCT06751121 ↗ |